Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 6 September 2024, including: Johnson & Johnson interested in differentiated obesity assets; Kerendia hits in heart failure; strong HERCULES data keep Sanofi’s MS plans alive; WCLC preview; and Mankind Pharma Ltd. sets eyes on 5x growth.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "J&J Interested In ‘Differentiated’ Obesity Assets" - Scrip, 4 September, 2024.)
(Also see "ESC: Kerendia Hits In Heart Failure, But Usage Unclear" - Scrip, 1 September, 2024.)
(Also see "Strong HERCULES Data Keep Sanofi’s MS Plans Alive" - Scrip, 2 September, 2024.)
(Also see "WCLC Preview: ADCs, Bispecifics And Other Targeted Therapies Command Attention" - Scrip, 2 September, 2024.)
(Also see "Fast And Furious – Leqvio Licensed, Bharat Serums In Bag, Mankind Sets Eyes On 5X Growth" - Scrip, 3 September, 2024.)
